Australia Wound Care Management Devices Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia wound care management devices market is shifting from hospital-centred dressing purchases towards funded, community-based care. Wounds were once managed episodically, whereas chronic wound care now draws on national training, home delivery and multidisciplinary foot services.

Three forces shape demand: the Chronic Wound Consumables Scheme, which supplies free products to eligible patients; a rising diabetes-related foot disease burden, with about 6,300 amputations a year; and domestic innovation in biomaterials and skin regeneration, led by PolyNovo and Avita Medical.

The scheme launched on 18 June 2025, the diabetes foot strategy followed in August 2025, Avita received TGA certification for RECELL GO in April 2026, and PolyNovo reported AUD 150.0 million of FY26 revenue in August 2026.

Key Market Trends and Insights

• Funded home supply: The Chronic Wound Consumables Scheme, launched on 18 June 2025 with AUD 47.8 million, expects to serve about 20,000 people a year and save an average of AUD 4,000 each in out-of-pocket costs.
• Diabetic foot burden: The Australian Strategy for Foot Health and Disease in Diabetes 2030 counts 510,000 Australians with diabetes-related foot disease, 47,100 hospitalisations and about 6,300 amputations every year.
• Local innovation scales: PolyNovo lifted FY26 revenue 16.1% to AUD 150.0 million, and its Asia Pacific commercial sales grew 33.6% to AUD 13.7 million, the fastest of its three regions.
• Reimbursement risk abroad: Convatec InnovaMatrix revenue fell 94% to USD 2.5 million in the first half of 2026 after a US Medicare payment change, showing how payer rules can reset skin substitute demand.

Australia Wound Care Management Devices Market Size and Forecast

The market is moving from episodic dressing purchases made by hospitals towards continuous, community-based care funded through national and state programs. Advanced dressings lead because they suit both chronic and acute wounds, while skin substitutes and biomaterials advance fastest as burns and complex wounds gain regenerative options. Surgical and traumatic wounds remain the largest wound type, but diabetic foot ulcers grow quickest as prevention and early intervention expand. Community and home care gains share most rapidly, and New South Wales stays the largest state while Western Australia grows fastest. Public funding, clinician training and domestic manufacturing point to durable demand rather than a cyclical lift.

Key Takeaways: Australia Wound Care Management Devices Market

Government Supply and Diabetes Burden Sustain Demand

Revenue is on course to rise by about 76% across the decade, from AUD 1,150.00 million in 2025 to AUD 2,020.95 million in 2035 at a 5.8% CAGR. The Chronic Wound Consumables Scheme and a diabetes foot disease burden costing an estimated AUD 2.7 billion a year make recurring dressing and device demand structural.

Biomaterials, Foot Ulcers and Home Care Lead Growth

Advanced Wound Dressings holds the largest revenue share, but Skin Substitutes and Biomaterials grow at an estimated 7.9% CAGR, Diabetic Foot Ulcers at 7.1% and Community and Home Care at 8.3% through 2035. PolyNovo NovoSorb MTX sales rose 89.6% in FY26, showing how quickly regenerative products can scale.

PolyNovo Builds Domestic Capacity for Regenerative Devices

PolyNovo reported FY26 results on 26 August 2026, with construction of its new manufacturing facility complete and a move planned in FY27. The result positions an Australian-developed device platform as a global supplier.

• Group revenue of AUD 150.0 million, up 16.1%
• Asia Pacific commercial sales of AUD 13.7 million, up 33.6%
• NovoSorb BTM sales of AUD 125.8 million, up 12.3%

Australia Wound Care Management Devices Market Report Summary

Key Insight

Funded home supply, a large diabetic foot burden and domestic innovation make this a structural category. Dressings lead, while biomaterials, foot ulcers and community delivery grow fastest.

Key Trends in the Australia Wound Care Management Devices Market

The Australia wound care management devices market is being shaped by population growth, remote foot care research, smart dressing science and national diabetes foot planning.

September 2026 - ABS Population Data Shows Western Australia Growing Fastest

• The Australian Bureau of Statistics reported on 17 September 2026 a national population of 27,921,150 at 31 March 2026, up 1.4%.
• Western Australia grew 2.1%, the fastest rate, while Tasmania grew 0.6%, the slowest.
• Faster population growth enlarges the future patient base in the west.

June 2026 - WA Country Health Service Maps Kimberley Foot Care Pathways

• WA Country Health Service announced on 5 June 2026 the Healing Steps on Country study of Aboriginal people with diabetes-related foot disease in the Kimberley.
• Nine in 10 patients needed hospitalisation for their foot at some point, according to the findings.
• Recommendations on training, telehealth and self-care point to more community-delivered wound products.

March 2026 - RMIT Develops Smart Dressing That Monitors and Treats Wounds

• RMIT University researchers published on 17 March 2026 a hydrogel dressing with carbon dots that changes colour when infection alters wound pH.
• The patch releases anti-inflammatory nanozymes automatically when infection signals appear.
• The team is seeking industry partners, since testing so far is laboratory-scale.

August 2025 - National Strategy Sets Diabetic Foot Targets to 2030

• Diabetes Feet Australia and La Trobe Rural Health School launched the Australian Strategy for Foot Health and Disease in Diabetes 2030 on 18 August 2025.
• Full implementation could avoid about 2,800 amputations and 20,000 hospital admissions a year, saving about AUD 940 million.
• Prevention-led care raises early dressing demand.

Key Insight

Demographics, regional care research and prevention-led national planning are widening the patient base, while smart dressing research shows where products may head. Growth is steady across the forecast period.

Recent Market Developments in the Australia Wound Care Management Devices Market

Recent developments, presented from the most recent, show the Australia wound care management devices market moving from the funded home supply scheme into regulatory approvals and local manufacturing scale.

August 2026 - PolyNovo Reports Record FY26 Revenue of AUD 150.0 Million

• PolyNovo reported on 26 August 2026 group revenue of AUD 150.0 million, up 16.1%, and commercial sales of AUD 138.4 million.
• NovoSorb BTM sales were AUD 125.8 million and NovoSorb MTX sales AUD 12.6 million, up 89.6%.
• Construction of the new manufacturing facility is complete, with transition planned for FY27.

April 2026 - Avita Medical Gains TGA Certification for RECELL GO

• AVITA Medical announced on 29 April 2026 that RECELL GO received TGA certification, enabling commercialisation in Australia and New Zealand.
• Revolution Surgical, its exclusive distributor, expected to launch within weeks, and one kit treats wounds up to 1,920 cm2.
• The system standardises enzyme incubation previously done manually.

September 2025 - TGA Authorises MediWound NexoBrid for Burn Debridement

• MediWound announced on 25 September 2025 that the TGA granted marketing authorisation for NexoBrid in Australia.
• Balance Medical, its exclusive partner, expected commercial launch in the fourth quarter of 2025.
• It removes eschar in adults and children with deep partial and full-thickness thermal burns.

June 2025 - Chronic Wound Consumables Scheme Opens to Eligible Patients

• The scheme launched officially on 18 June 2025 with AUD 47.8 million, and about 3,500 clinicians had enrolled at launch.
• It supplies free products to people with diabetes and a chronic wound who are aged 65 or over, or 50 or over if First Nations.
• Independence Australia Group was appointed in April 2025 to distribute products nationwide, including remote areas.

Key Insight

Recent activity combines regulatory approvals, domestic manufacturing scale and a funded national supply program. Together they show regenerative products and community delivery moving from pilot stage into routine supply.

Australia Wound Care Management Devices Industry Segmentation

The Expert Market Research’s report on the Australia Wound Care Management Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Advanced Wound Dressings
• Traditional Wound Dressings
• Negative Pressure Wound Therapy
• Skin Substitutes and Biomaterials
• Others

Advanced Wound Dressings leads, as Mölnlycke lists Mepilex Border Flex, Mepilex Ag, Exufiber and Mepilex Up on the Chronic Wound Consumables Scheme and Smith+Nephew credited ALLEVYN COMPLETE CARE foam for dressing growth in its second quarter of 2026. Skin Substitutes and Biomaterials grows fastest at an estimated 7.9% CAGR through 2035, helped by PolyNovo NovoSorb MTX sales rising 89.6% in FY26 and Avita RECELL GO certification in April 2026. Negative Pressure Wound Therapy rests on V.A.C. Therapy, sponsored in Australia by Solventum subsidiary KCI Medical Australia, and ConvaTec Australia single-use systems. Traditional Wound Dressings cover gauze, tapes and bandages bought by hospitals and pharmacies. Others include compression, offloading and debridement devices.

Market Breakup by Wound Type

• Diabetic Foot Ulcers
• Pressure Injuries
• Venous Leg Ulcers
• Surgical and Traumatic Wounds
• Others

Surgical and Traumatic Wounds leads because hospitals treat them in volume and the consumables scheme excludes acute surgical wounds, so hospital contracts supply them. Diabetic Foot Ulcers grows fastest at an estimated 7.1% CAGR through 2035, as a Queensland study published in July 2025 found that 20.7% of 4,709 clinic patients were hospitalised within two years and the national strategy launched in August 2025. Pressure Injuries and Venous Leg Ulcers are both eligible under the scheme for people with diabetes, supporting steady dressing demand. Others include burns, where NexoBrid gained TGA authorisation in September 2025 and RECELL GO in April 2026.

Market Breakup by End User

• Hospitals
• Aged Care Facilities
• Community and Home Care
• Specialist Wound and Podiatry Clinics
• Others

Hospitals lead because acute wounds and complex foot ulcers are treated there, and Armadale Health Service opened a weekly multidisciplinary foot ulcer clinic in Western Australia in June 2025. Community and Home Care grows fastest at an estimated 8.3% CAGR through 2035, as the scheme delivers products to homes and Independence Australia Group distributes them nationwide. Aged Care Facilities buy mostly through private supply, because the scheme excludes government-funded aged care. Specialist Wound and Podiatry Clinics gain from Monash training modules, announced in April 2025 and required for scheme clinicians. Others include pharmacies, where Smith+Nephew presented at the APP2025 conference in March 2025.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates with 8.67 million residents in March 2026, and it grows at an estimated 5.5% CAGR through 2035. Western Australia is fastest at an estimated 6.7%, as its population grew 2.1% in the year to March 2026 and WA Country Health Service launched its Kimberley foot care study in June 2026. Victoria, at an estimated 5.8%, hosts PolyNovo, RMIT and La Trobe University. Queensland grows at 6.2% on 5.74 million residents, and South Australia at 5.2% on 1.92 million. Others covers Tasmania, the ACT and the Northern Territory, growing at an estimated 5.9%, where the Northern Territory had a diabetes-related lower-limb amputation rate of 65 per 100,000 in November 2025.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Wound Care Management Devices Market

Competition combines global wound care groups, Australian device developers and distributors serving the national supply scheme. Barriers include TGA sponsorship and ARTG listing, hospital and state tender relationships, clinician education capacity and clinical evidence.

Smith+Nephew

Smith+Nephew, headquartered in Watford, England, was founded in 1856 in Hull and sells ALLEVYN foam, OPSITE, CICA-CARE and SOLOSITE dressings in the Australian pharmacy channel, and negative pressure systems. Advanced Wound Management sales were USD 456 million in the second quarter of 2026, with LEAF patient monitoring growing at a double-digit rate. It launched ALLEVYN COMPLETE CARE and the RENASYS EDGE system at EWMA in Bremen in May 2026.

Convatec

Convatec, listed on the London Stock Exchange, began in 1978 as a division of E.R. Squibb and Sons, and ConvaTec Australia Pty Ltd holds TGA entries for Aquacel Ag Extra dressings and single-use negative pressure systems. First half 2026 results on 4 August 2026 showed Advanced Wound Care revenue of USD 354 million excluding InnovaMatrix, up 3.4% organically, and a new USD 200 million buyback running to the end of 2026.

Mölnlycke Health Care

Mölnlycke Health Care traces its roots to Mölnlycke Väfveri AB, founded in 1849, and supplies Mepilex Border Flex, Mepilex Ag, Exufiber and Mepilex Up through the Chronic Wound Consumables Scheme, according to its Australian site updated in April 2026. In September 2026 it announced plans to separate its Operating Room Solutions and Gloves businesses into a standalone company named Mölnlycke Surgical.

PolyNovo

PolyNovo, headquartered in Melbourne and listed on the ASX, developed NovoSorb BTM with CSIRO and holds TGA registration. FY26 revenue reached AUD 150.0 million, up 16.1%, and Asia Pacific commercial sales rose 33.6% to AUD 13.7 million. Chief executive Bruce Peatey leads a strategy that includes a planned US premarket approval submission and a transition to its new manufacturing facility in FY27.

Other players operating in the Australia wound care management devices market include Solventum, Coloplast, Paul Hartmann, Independence Australia Group, and Avita Medical, alongside specialist distributors, pharmacy suppliers, and compression and offloading device makers supporting hospitals, aged care providers and community clinicians across Australia.

Key Insight

Competition rests on regulatory listing, clinical evidence, tender access and education support rather than price alone. Global groups anchor supply, while domestic developers compete through proprietary biomaterials.